ClinicalTrials.gg
CompletedNCT05335122Updated Sep 3, 2026Results posted

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

A Phase 2 interventional study of OTX-TIC low dose Travoprost Intracameral Implant and OTX-TIC high dose Travoprost Intracameral Implant in Open Angle Glaucoma and Ocular Hypertension, sponsored by Ocular Therapeutix, Inc.. Completed at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Ocular Therapeutix, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
141st of 279
83 · median 84
Started
2022
with 12 others
Phase 2
76 of 348
5 open now
Registered
271st of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 141st largest by enrollment of the 279 interventional ones that give a count, is one of 13 that started in 2022, is one of 76 in phase 2, and was the 271st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Read the detailed description

This is a prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy, and safety of OTX-TIC (travoprost) intracameral implant in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT). Approximately 105 subjects will be enrolled in this study at approximately 20 sites in the US. Subjects will be a randomized to one of three treatment groups OTX-TIC drug product (2 travoprost dose strengths) compared to a single injection of DurystaTM. Non study eyes will be treated with the PGA, if not contraindicated.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 years of age or older at the time of screening
  • Provide written and are able to comply with all study requirements
  • Are willing to withhold glaucoma medications according to the study requirements, and in the opinion of the investigator can do so without significant risk
  • Have a negative pregnancy test result for women of at Baseline
  • Have a documented diagnosis of OHT, or OAG in the study eye

Exclusion criteria

Exclusion Criteria:

  • Have an uncontrolled systemic disease or a debilitating disease (e.g., cardiovascular, hypertension, uncontrolled diabetes)
  • Are currently pregnant or breast-feeding or of without the use of adequate methods during the length of the study
  • Non-responsive to topical prostaglandins, prostamides or prostaglandin analogs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    OTX-TIC Low Dose

    Travoprost Intracameral Implant low dose

    Drug: OTX-TIC low dose Travoprost Intracameral Implant

  • Experimental
    OTX-TIC High Dose

    Travoprost Intracameral Implant high dose

    Drug: OTX-TIC high dose Travoprost Intracameral Implant

  • Active comparator
    Durysta

    Bimatoprost Intracameral Implant 10 µg

    Drug: Durysta, Bimatoprost Intracameral Implant 10 µg

Interventions

  • DrugOTX-TIC low dose Travoprost Intracameral Implant

    OTX-TIC implant is injected into the anterior chamber of the eye.

  • DrugOTX-TIC high dose Travoprost Intracameral Implant

    OTX-TIC implant is injected into the anterior chamber of the eye.

  • DrugDurysta, Bimatoprost Intracameral Implant 10 µg

    Durysta is injected into the anterior chamber of the eye.

06

What researchers measure

Primary outcomes

  1. IOP Changes From Baseline in the Study Eye

    IOP changes from baseline 8 AM, 10 AM, and 4 PM at Week 2, Week 6, and Week 12 in the study eye.

    Time frame: Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM)

07

Results

Posted Sep 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneOTX-TIC 5 µgOTX-TIC 26 µgDurysta
Started163234
Completed163032
Not completed022
Withdrew: Adverse event010
Withdrew: Physician decision010
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryIOP Changes From Baseline in the Study Eye

IOP changes from baseline 8 AM, 10 AM, and 4 PM at Week 2, Week 6, and Week 12 in the study eye.

Time frame:
Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM)
Reported as:
Mean · Millimeter of Mercury (mmHg)
IOP Changes From Baseline in the Study Eye
Millimeter of Mercury (mmHg)OTX-TIC 5 µgOTX-TIC 26 µgDurysta
Change from Baseline (8 AM) to Week 2 (8 AM)-7.69 ± 3.807-7.66 ± 4.243-7.03 ± 3.567
Change from Baseline (10 AM) to Week 2 (10 AM)-6.37 ± 3.287-7.34 ± 4.786-6.21 ± 3.162
Change from Baseline (4 PM) to Week 2 (4 PM)-5.47 ± 3.507-6.23 ± 4.291-6.19 ± 3.071
Change from Baseline (8 AM) to Week 6 (8 AM)-7.81 ± 3.130-7.70 ± 3.692-7.09 ± 3.762
Change from Baseline (10 AM) to Week 6 (10 AM)-6.40 ± 3.318-7.00 ± 4.049-5.97 ± 3.665
Change from Baseline (4 PM) to Week 6 (4 PM)-5.53 ± 2.682-5.81 ± 3.823-5.87 ± 3.391
Change from Baseline (8 AM) to Week 12 (8 AM)0.68 ± 13.476-7.03 ± 3.610-6.13 ± 3.799
Change from Baseline (10 AM) to Week 12 (10 AM)-1.38 ± 9.366-6.12 ± 3.729-5.58 ± 3.170
Change from Baseline (4 PM) to Week 12 (4 PM)-1.42 ± 8.149-5.38 ± 3.651-5.79 ± 2.969

Adverse events

Collected over From time of administration of study drug to last visit (up to 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-TIC 5 µg0/16 (0%)1/16 (6.3%)12/16 (75%)
OTX-TIC 26 µg0/32 (0%)6/32 (18.8%)20/32 (62.5%)
Durysta0/34 (0%)4/34 (11.8%)8/34 (23.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventOTX-TIC 5 µgOTX-TIC 26 µgDurysta
Rib FractureInjury, poisoning and procedural complications1/160/320/34
IritisEye disorders0/161/320/34
FallInjury, poisoning and procedural complications0/161/320/34
Electrolyte ImbalanceMetabolism and nutrition disorders0/161/320/34
Mental Status ChangesPsychiatric disorders0/161/320/34
Renal ImpairmentRenal and urinary disorders0/161/320/34
Diabetic FootSkin and subcutaneous tissue disorders0/161/320/34
Upper Limb FractureInjury, poisoning and procedural complications0/160/321/34
WoundInjury, poisoning and procedural complications0/160/321/34
PyuriaInfections and infestations0/160/321/34
Most frequent other events
Showing 10 of 27
Most frequent other events
EventOTX-TIC 5 µgOTX-TIC 26 µgDurysta
Intraocular Pressure IncreasedInvestigations6/162/321/34
IritisEye disorders3/167/321/34
Punctate KeratitisEye disorders1/166/322/34
Eye PainEye disorders3/164/320/34
Conjunctival HyperaemiaEye disorders1/165/320/34
Conjuctival HaemorrhageEye disorders2/161/322/34
Foreign Body Sensation in EyeEye disorders2/162/321/34
EpiscleritisEye disorders2/161/320/34
PhotophobiaEye disorders2/161/320/34
Eye InflammationEye disorders2/160/320/34

Baseline characteristics

Baseline characteristics will be based on mITT population.

Age, Categorical
Age, Categorical(Participants)OTX-TIC 5 µgOTX-TIC 26 µgDurystaTotal
<=18 years0000
Between 18 and 65 years8131536
>=65 years8191946
Age, Continuous
Age, Continuous(years)OTX-TIC 5 µgOTX-TIC 26 µgDurystaTotal
Mean61.3 ± 10.2965.1 ± 8.8264.9 ± 12.864.3 ± 10.88
Sex: Female, Male
Sex: Female, Male(Participants)OTX-TIC 5 µgOTX-TIC 26 µgDurystaTotal
Female8151538
Male8171944
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTX-TIC 5 µgOTX-TIC 26 µgDurystaTotal
Hispanic or Latino34714
Not Hispanic or Latino13282768
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTX-TIC 5 µgOTX-TIC 26 µgDurystaTotal
American Indian or Alaska Native0101
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American47617
White12242662
More than one race0011
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)OTX-TIC 5 µgOTX-TIC 26 µgDurystaTotal
United States16323482
08

Study locations

30 sites
  • Ocular Therapeutix, Inc.
    Dothan, Alabama 36301, United States
  • Ocular Therapeutix, Inc.
    Huntington Beach, California 92647, United States
  • Ocular Therapeutix, Inc.
    Irvine, California 92604, United States
  • Ocular Therapeutix, Inc.
    Los Angeles, California 90013, United States
  • Ocular Therapeutix, Inc.
    Pasadena, California 91107, United States
  • Ocular Therapeutix, Inc.
    Petaluma, California 94954, United States
  • Ocular Therapeutix, Inc.
    Redlands, California 92373, United States
  • Ocular Therapeutix, Inc.
    Torrance, California 90505, United States
  • Ocular Therapeutix, Inc.
    Clearwater, Florida 33761, United States
  • Ocular Therapeutiux, Inc.
    Delray Beach, Florida 33484, United States
  • Ocular Therapeutix, Inc.
    Fort Myers, Florida 33901, United States
  • Ocular Therapeutix, Inc.
    Roswell, Georgia 30076, United States
  • Ocular Therapeutix, Inc.
    Rock Island, Illinois 61201, United States
  • Ocular Therapeutix Inc
    Carmel, Indiana 46032, United States
  • Ocular Therapeutix, Inc.
    Saint Joseph, Michigan 49085, United States
  • Ocular Therapeutix, Inc.
    Saint Joseph, Missouri 49085, United States
  • Ocular Therapeutix Inc.
    St Louis, Missouri 63110, United States
  • Ocular Therapeutix, Inc.
    Dover, New Jersey 07801, United States
  • Ocular Therapeutix, Inc.
    Troy, New York 12108, United States
  • Ocular Therapeutix, Inc.
    Durham, North Carolina 27710, United States
  • Ocular Therapeutiux, Inc.
    Fargo, North Dakota 58103, United States
  • Ocular Therapeutix, Inc.
    Cleveland, Ohio 44106, United States
  • Ocular Therapeutix Inc
    Oklahoma City, Oklahoma 73112, United States
  • Ocular Therapeutix, Inc.
    Cranberry Township, Pennsylvania 16066, United States
  • Ocular Therapeutix, Inc.
    Philadelphia, Pennsylvania 19107, United States
  • Ocular Therapeutix, Inc.
    Austin, Texas 78701, United States
  • Ocular Therapeutix, Inc.
    Dallas, Texas 75231, United States
  • Ocular Therapeutix, Inc.
    El Paso, Texas 79902, United States
  • Ocular Therapeutix, Inc.
    Houston, Texas 77030, United States
  • Ocular Therapeutix, Inc.
    Kenosha, Wisconsin 53142, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jan 2024, 22 months.

Results were first posted in Sep 2026, 2 years 7 months after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 22 months is above that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 19, 2022
StartActual
Mar 16, 2022
Primary completionActual
Jan 24, 2024
CompletionActual
Jan 24, 2025
Results first posted
Sep 3, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05335122
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
Mar 16, 2022
Primary completion
Jan 24, 2024
Completion
Jan 24, 2025
Results posted
Sep 3, 2026
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion